Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.9 -3.05 (-1.13%) Market Cap: 34.30 Bil Enterprise Value: 33.17 Bil PE Ratio: 0 PB Ratio: 1,063.60 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 06:20PM GMT
Release Date Price: $120.42 (-6.05%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Sorry, it's still good morning here. I'm Tazeen Ahmad. I'm one of the senior SMid Biotech analyst here at Bank of America. It's my pleasure to have with us at the BofA Healthcare Conference. Our next presenting company Alnylam Pharmaceuticals. Sitting next to me and presenting for the company is CFO, Jeffrey Poulton. Jeff, good morning. Welcome to Las Vegas. Thanks for joining us at our conference.

Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP

It's nice to be here. I think everyone's probably seeing in person for the first time in a long time. Nice to be here.

Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Yes. First time in 3 years we're back. So I don't know that anyone needs an intro on Alnylam, but for the heck of it maybe you can spend a couple of minutes just talking about the company and the platform and some of the recent updates, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot